| Basics |
Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.
|
| IPO Date: |
October 1, 2002 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$82.13M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.14 | 3.87%
|
| Avg Daily Range (30 D): |
$0.07 | 5.13%
|
| Avg Daily Range (90 D): |
$0.05 | 4.10%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.32M |
| Avg Daily Volume (30 D): |
.17M |
| Avg Daily Volume (90 D): |
.29M |
| Trade Size |
| Avg Trade Size (Sh.): |
259 |
| Avg Trade Size (Sh.) (30 D): |
166 |
| Avg Trade Size (Sh.) (90 D): |
198 |
| Institutional Trades |
| Total Inst.Trades: |
47 |
| Avg Inst. Trade: |
$1.96M |
| Avg Inst. Trade (30 D): |
$.8M |
| Avg Inst. Trade (90 D): |
$.92M |
| Avg Inst. Trade Volume: |
.39M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.96M |
| Avg Closing Trade (30 D): |
$1.04M |
| Avg Closing Trade (90 D): |
$1.04M |
| Avg Closing Volume: |
917.3K |
|
|
|
|
| Financials |
| |
TTM |
Q4 2024 |
FY 2024 |
|
Basic EPS
|
$-.76
|
$-.19
|
$-.76
|
|
Diluted EPS
|
$-.76
|
$-.19
|
$-.76
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -47.05M
|
$ -11.97M
|
$ -47.05M
|
|
Operating Income / Loss
|
$ -42.43M
|
$ -12.43M
|
$ -42.43M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ M
|
$ M
|
$ M
|
|
PE Ratio
|
|
|
|
|
